The global heterozygous familial hypercholesterolemia (HEFH) management market is expected to be worth USD 15.11 Billion in the fiscal year 2023, which rose up from USD 13.2 Billion in the fiscal year 2022. From 2023 to 2033, the global market is expected to grow at a 14.5% CAGR, reaching a value of USD 58.54 Billion by the end of 2033.
Familial hypercholesterolemia (FH) is a hereditary disorder that results in high levels of low-density lipoprotein (LDL) cholesterol (also known as bad cholesterol) from birth. FH stands for familial hypercholesterolemia. FH is caused by unique DNA alterations that are handed down from one generation to the next. It is not caused by elements in one's lifestyle, including a high-fat diet or even a lack of exercise.
Without therapy, HEFH causes exceedingly high LDL as well as total cholesterol levels. Excess LDL cholesterol can clump together and create plaque in the artery walls. The plaque constricts the arteries, allowing less blood to flow through them. This is referred to as artery hardening. Whenever this happens, the heart must exert more effort to circulate blood throughout the body.
The heart can be damaged over time, resulting in heart disease. If this occurs, one of the primary symptoms is chest discomfort known as angina. This could result in a heart attack or even stroke if not treated. Thus, this disease needs to be treated at the earliest, and such reasons are why there is a surge in demand within the Heterozygous Familial Hypercholesterolemia (HEFH) management market globally.
| Data Points | Key Statistics |
|---|---|
| Anticipated Base Year Value (2022) | USD 13.2 Billion |
| Expected Market Value (2023) | USD 15.11 Billion |
| Projected Forecast Value (2033) | USD 58.54 Billion |
| Global Growth Rate (2023 to 2033) | 14.5% |
| CAGR of North America (2023) | 15.3% |
| CAGR of Europe (2023 to 2033) | 14% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global heterozygous familial hypercholesterolemia (HEFH) management Market grew at a CAGR of 9.2% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.
The prevalence of chronic illnesses and cardiovascular diseases, as well as an increase in the number of clinical trials along with research studies for the management of heterozygous familial hypercholesterolemia, are major drivers of the market's revenue growth. The current explosive growth of clinical medication innovation for hypercholesterolemia is another factor that is projected to fuel market revenue growth.
Due to technological advancements in the treatment of heterozygous familial hypercholesterolemia, enhanced healthcare facilities, greater research and drug development for the diagnosis, government initiatives to raise public awareness of the symptoms, causes, and therapeutic options for this type of hypercholesterolemia, as well as increased healthcare investments, it is predicted that the market will experience abundant opportunities for growth during the forecast period.
Such factors are expected to boost the global sales of Heterozygous Familial Hypercholesterolemia (HEFH) management solutions. As a result, the global Heterozygous Familial Hypercholesterolemia (HEFH) Management Market is expected to forecast a CAGR of over 14% from 2023 to 2033.
Unhealthy Lifestyles and Aging Population to Boost Demand
One of the main factors fueling the market's expansion is the increased prevalence of HEFH brought on by the general public's increasingly unhealthy lifestyle. This is supported by the growing geriatric population, which is vulnerable to cardiovascular illnesses (CVDs) and a number of other chronic diseases, including diabetes, renal troubles, and thyroid issues.
Additionally, other growth-promoting variables include the growing interest in health and the understanding of the many treatment options for HEFH management. Such factors are sure to propel the market for Heterozygous Familial Hypercholesterolemia (HEFH) management during the forecast period.
Increasing Research and Development and New Product Launches to accelerate Market Expansion
The launch of numerous medications and treatments to help hypercholesterolemia patients reach near-normal lipid profiles and lower their risk of developing CVD is giving market growth a significant boost. In addition, the creation of new medication classes with improved effectiveness and safety profiles is boosting market expansion. The introduction of numerous combination medicines to treat hypercholesterolemia that also contain other cholesterol-lowering substances is also contributing to the market's expansion.
In addition, the statins' widespread use is promoting market expansion due to their numerous benefits, including improved endothelial function, reduced oxidative stress-induced cell damage, higher atherosclerotic plaque stability, and lower inflammation. Such developments are expected to accelerate the demand for Heterozygous Familial Hypercholesterolemia (HEFH) management during the forecast period.
Principal Consultant
Lack of Awareness and Knowledge to Impede Expansion
Both healthcare professionals and the general population are unaware of FH. As a result, it receives insufficient attention and care. Untreated HEFH patients have a 20x higher risk of developing coronary artery disease than HEFH-free individuals.
Heart attacks, stroke, and sudden cardiac death are all important cardiovascular disorders that can be brought on by coronary artery disease. However, this risk can be decreased with an early diagnosis with universal lipid screening, cascade screening in families, and effective treatment using statins and other drugs.
Rising Clinical Studies and Trials to boost Regional Demand
North America is predicted to hold the dominant market share of 41% revenue share in 2023 and is the fastest-growing market for Heterozygous Familial Hypercholesterolemia (HEFH) management, with a dominant 15.3% CAGR from 2023 to 2033. Growth can be attributed to the increasing research and developments by the key players in this region. At the same time, the huge number of clinical trials and studies being conducted on heterozygous familial hypercholesterolemia for the proper treatment are also accelerating the demand in the regional market.
For example, Ionis Pharmaceuticals, Inc., a pioneer in antisense therapeutics, and its collaborator AstraZeneca announced in 2022 that the ETESIAN Phase 2b study of ION449 (AZD8233), an investigational antisense drug intended to lower blood cholesterol levels in people with hypercholesterolemia by trying to target proprotein convertase subtilisin/kexin type 9 in mice, had shown positive results (PCSK9). The 71st Annual Scientific Session & Expo of the American College of Cardiology featured the presentation of these results.
The goal of the ETESIAN Phase 2b research was to evaluate ION449's effectiveness, safety, and tolerability in individuals with high-risk hypercholesterolemia. The study's primary goal of lowering blood LDL-C levels by up to 79% was achieved. Hence, there would be a lot of scope for North American manufacturers to develop in this market during the forecast period.
Increasing Treatment Options and Innovations to augment Treatment Incidences
During the forecast period, the European market for Heterozygous Familial Hypercholesterolemia (HEFH) management is expected to garner a steady CAGR of 14%. But at the time, the European market for the management of heterozygous familial hypercholesterolemia (HEFH) is expected to witness this market gain of 31% in 2023. Expanding research and innovations by the key players and various projects being approved for the management of Heterozygous Familial Hypercholesterolemia and increasing authorizations of the clinical trials by some prominent companies in the region are propelling the growth.
Verve Therapeutics, Inc., a clinical-stage biopharmaceutical company that is developing single-course gene editing drugs to treat cardiovascular disease, declared in 2022 that the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) had approved its Clinical Trial Authorization (CTA) application for VERVE-101 as a prospective treatment for people with heterozygous familial hypercholesterolemia (HeFH). HeFH is a common hereditary variant of atherosclerotic cardiovascular disease (ASCVD) that can be fatal and is characterized by abnormally high blood levels of the disease-causing lipid LDL-cholesterol (LDL-C). Such developments are expected to accelerate the growth in the market from 2023 to 2033.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
ST-103-based Drugs to be Most Preferred Treatment Option
Over the course of the forecast period, ST-103-based drugs are anticipated to occupy a significant share of treating heterozygous familial hypercholesterolemia. In 2023, this category is anticipated to dominate with a 32% revenue share.
ST-103 is a popular statin. Since statins are advised for use in the therapy of hypercholesterolemia because of their safety and efficacy, it has been concluded that they constitute a substantial revenue generator among the market segments evaluated. Statins are the most popular treatment for hypercholesterolemia because they totally block the enzyme HMG-CoA reductase, which is in charge of producing cholesterol.
In addition, statins are engaged in lowering LDL cholesterol levels and raising HDL cholesterol levels. Such factors are expected to accelerate the growth prospects for Heterozygous Familial Hypercholesterolemia (HEFH) management from 2023 to 2033.
The start-ups strive to set their goods apart on the global market by incorporating cutting-edge technology and enhanced safety measures. The symptoms are being treated first, of course, and also various metrics are being measured to check the present condition of the patient. Some of the companies are:
Some of the prominent players in the global market for heterozygous familial hypercholesterolemia (HEFH) management are:
Some of the prominent developments of the key players in the market are:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 15.11 Billion |
| Market Value in 2033 | USD 58.54 Billion |
| Growth Rate | CAGR of 14.5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
Product Type, Application, Region |
| Regions Covered |
North America; Latin America; Europe; Asia Pacific; Middle East and Africa |
| Key Countries Profiled |
USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, Thailand, Singapore, Indonesia, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled |
Sanofi SA; Amgen Inc.; Novartis International AG; AdooQ Bioscience; Thermo Fisher Scientific; Universal Biologicals; Selleck Chemicals; Madrigal Pharmaceuticals; Shanghai Caerulum Pharma Discovery Co., Ltd.; Wuhan Biocar Pharmacy |
| Customization | Available Upon Request |
The United States generated 28% of the global demand in 2022.
The Asia Pacific market is expected to record a 9.2% CAGR through 2033.
Small molecule drugs segment contributes 72% of total production.
Oral segment holds 57% of the global market share.
From 2018 to 2022, the global market exhibited 9.2% CAGR.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type 5.1. Gemcabene Calcium 5.2. MGL-3196 5.3. ST-103 5.4. Others 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 6.1. Hospitals 6.2. Medical Centres 6.3. Clinics 6.4. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. Asia Pacific 7.5. Middle East and Africa (MEA) 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Key Countries Market Analysis 14. Market Structure Analysis 15. Competition Analysis 15.1. Sanofi SA 15.2. Amgen Inc. 15.3. Novartis International AG 15.4. AdooQ Bioscience 15.5. Thermo Fisher Scientific 15.6. Universal Biologicals 15.7. Selleck Chemicals 15.8. Madrigal Pharmaceuticals 15.9. ShangHai Caerulum Pharma Discovery Co., Ltd. 15.10. Wuhan Biocar Pharmacy 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports
Heterozygous Familial Hypercholesterolemia (HEFH) Management Market
